ondasdechoque.org
PT-BR

Rotator-cuff / subacromial pain: mixed or unspecified subtype · Review · 2014

When does a Dutch guideline suggest shockwave for shoulder pain?

This Dutch guideline from 2014 says high-energy shockwave can be considered when calcium deposits in the shoulder tendons are confirmed. Needle rinsing of the deposit is the other option it lists. It advises against shockwave in the acute phase or when there are no calcium deposits.

year the guideline was published
2014
options it lists for calcium deposits
2
clinical questions covered
8

Good to know: This is guideline advice, not a trial; it gives no shockwave dose or measured results.

Diercks R, Bron C, Dorrestijn O, et al. Acta Orthopaedica, 2014 · Read the paper ↗

How this study worked

One answer
A review gathers earlier studies to answer one question. Illustration, not to scale.

Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.

What the trials used

ESWT indication and protocol detail
The guideline says high-energy ESWT can be considered for confirmed subacromial calcium deposits and is not recommended in the acute phase or without calcific tendinosis/bursitis. Device, focused/radial type, energy, pulses, sessions and comparator are not specified.

Who took part

Not a trial: a multidisciplinary Dutch guideline for people with subacromial shoulder pain, including those with calcium deposits.

Side effects

The guideline does not report side effects of shockwave.

All the numbers and the full appraisal

Every reported result

FROM THE FULL PAPER

What the full paper reports.

Multidisciplinary Dutch guideline/review addressing subacromial pain syndrome (SAPS), including calcific tendinosis as a distinct subgroup; not a trial cohort.

High-energy ESWT for calcific tendinosis1 reported outcome
01
Not stated

High-energy ESWT for calcific tendinosis

No numeric outcome estimate in guideline

The guideline states ESWT or ultrasound-guided needling/barbotage can be used for calcific tendinosis. Its Level 1 evidence conclusion, citing one systematic review (Huisstede et al. 2011), is that high-energy ESWT reduces pain and improves shoulder function more than low-energy ESWT or placebo in calcific tendinosis. It gives no numeric effect; citing Diehl et al. 2011, it finds no obvious preference among ESWT, barbotage and surgical removal, and advises against surgery because equivalent alternatives exist.

Analysis details and source

This is a guideline recommendation resting on a Level 1 conclusion from the cited review (the working group used consensus only where evidence was lacking), not a treatment trial result. The underlying ESWT studies were not independently reread for this extraction.

ESWT for acute or non-calcific SAPS1 reported outcome
02
Not stated

ESWT for acute or non-calcific SAPS

Recommendation; no numeric estimate

The guideline advises against ESWT in the acute phase and when calcific tendinosis/bursitis is absent. Its Level 1 conclusion (Huisstede et al. 2011) is that ESWT of any form is no more effective than placebo or other treatments for pain or shoulder function without calcium deposits.

Analysis details and source

The recommendation is diagnosis-specific and should not be generalized to calcific disease. No independent primary-trial estimate is provided here.

How treatment was delivered
ESWT indication and protocol detail

The guideline says high-energy ESWT can be considered for confirmed subacromial calcium deposits and is not recommended in the acute phase or without calcific tendinosis/bursitis. Device, focused/radial type, energy, pulses, sessions and comparator are not specified.

HARMS & TOLERABILITY

This guideline section does not provide comparative adverse-event counts or systematic ESWT harm monitoring.

LIMITS OF THE ANALYSIS

The authors describe heterogeneity in populations, factors, follow-up and outcome measures, with some uncertainty distinguishing SAPS from broader shoulder/neck pain.

The document is a 2014 guideline review; it provides no ESWT-specific trial outcome table, dose specification, or comparative effect estimate. Current applicability depends on later evidence not covered here.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • The authors describe heterogeneity in populations, factors, follow-up and outcome measures, with some uncertainty distinguishing SAPS from broader shoulder/neck pain.
  • The document is a 2014 guideline review; it provides no ESWT-specific trial outcome table, dose specification, or comparative effect estimate. Current applicability depends on later evidence not covered here.
Research review

Source-linked critical reading

Clinical guideline supported by an evidence review

Reading depthMaterial consulted
Technical source record

Complete HTML text read, all three raw tables and ESWT recommendation passages cross-checked; underlying primary trials unavailable.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Guideline and evidence base

Multidisciplinary guideline/review by the Dutch Orthopaedic Association; eight clinical questions; exploratory searches and evidence-level synthesis.

Population and scope

People with subacromial pain syndrome; recommendations distinguish acute/chronic symptoms, rotator-cuff disorders and calcific tendinosis. This is not a treatment trial.

ESWT protocol

High-energy ESWT may be considered for confirmed calcific deposits. Device, focus/radial type, energy, shocks and sessions are not specified.

Comparators

The guideline discusses exercise, injections, ultrasound-guided barbotage, imaging, rehabilitation and surgery; it does not provide a direct ESWT comparator trial in the extracted recommendation.

Outcomes

No numeric ESWT pain/function outcome, follow-up or comparative estimate is supplied. The recommendation is that ESWT or barbotage may be used for calcific tendinosis.

Comparative findings

No numeric estimate is given. Citing Diehl et al. 2011, the guideline finds no obvious preference among ESWT, barbotage and surgical removal for calcific tendinosis. The guideline's Level 1 conclusion, from one cited systematic review, is that high-energy ESWT beats low-energy ESWT or placebo in calcific tendinosis, while ESWT is no better than placebo or other treatments without calcium deposits. The guideline advises against ESWT in acute SAPS and when calcification is absent.

Harms

No systematic ESWT adverse-event data or comparison is given.

Limitations

Evidence synthesis reports heterogeneous populations, outcome measures and follow-up; SAPS definitions overlap with general shoulder/neck pain. Document dates from 2014; underlying evidence was not rechecked.

Applicability

Apply only to the specific calcific subgroup and interpret as older guideline advice, not a current dose recommendation or quantified benefit.

What further evidence needs

Updated comparative reviews and trials should report confirmed diagnosis, calcification status, ESWT type/dose, comparator, patient-important outcomes and harms.

THE ORIGINAL SOURCE

Read the original article.

Guideline for diagnosis and treatment of subacromial pain syndrome: a multidisciplinary review by the Dutch Orthopaedic Association.

Diercks R, Bron C, Dorrestijn O, Meskers C, Naber R, de Ruiter T, Willems J, Winters J, van der Woude HJ, Dutch Orthopaedic Association. · Acta orthopaedica · 2014

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →